Immuron Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steve Lydeamore

Chief Executive Officer (CEO)

AU$599.1k

Compensación total

Porcentaje del salario del CEO	72.7%
Permanencia del CEO	2.4yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.9yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Lydeamore en comparación con los beneficios de Immuron?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$599k	AU$436k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$4m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$584k	AU$415k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	n/a	n/a	-AU$3m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$781k	AU$6k	-AU$3m

Compensación vs. Mercado: La compensación total de Steve($USD389.35K) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD297.98K).

Compensación vs. Ingresos: La compensación de Steve ha aumentado mientras la empresa no es rentable.

CEO

Steve Lydeamore (56 yo)

2.4yrs

Permanencia

AU$599,135

Compensación

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as Chief Executive Officer at Immuron Limited since June 27, 2022. He served as the Chief Executive Officer of Anatara Lifesciences Limite...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lydeamore	Chief Executive Officer	2.4yrs	AU$599.14k	sin datos
Jerry Kanellos	Chief Operating Officer	9.3yrs	AU$359.25k	0.15% A$ 25.0k
Flavio Palumbo	Chief Commercial Officer	2yrs	AU$347.61k	sin datos
Phillip Hains	CFO & Company Secretary	11.6yrs	sin datos	0.36% A$ 61.3k
David Lyon	Head of Marketing	no data	sin datos	sin datos

5.9yrs

Permanencia media

59.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMC es experimentado (5.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Glenn Tillotson	Member of Advisory Board	no data	sin datos	sin datos
Jeannette Joughin	Independent Non-Executive Director	less than a year	AU$7.55k	0% A$ 0
Daniel Pollock	Independent Non-Executive Director	12.1yrs	AU$127.65k	0.36% A$ 61.4k
Paul Brennan	Independent Non-Executive Chairman	2.7yrs	AU$153.60k	0% A$ 0
Dena Lyras	Member of Advisory Board	no data	sin datos	sin datos
Ravi Savarirayan	Independent Non-Executive Director	7.6yrs	AU$75.00k	0.38% A$ 65.8k
Sahil Khanna	Member of Advisory Board	no data	sin datos	sin datos
Paul Feuerstadt	Member of Advisory Board	no data	sin datos	sin datos
Teena Chopra	Member of Advisory Board	no data	sin datos	sin datos

5.1yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de IMC se considera experimentada (5.1 años de antigüedad promedio).

Immuron Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited, Annual General Meeting, Nov 21, 2023

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

New major risk - Share price stability

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Insufficient new directors

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.87

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad